Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Shares Issued (2020 - 2025)

Oncology Institute (TOI) has disclosed Shares Issued for 5 consecutive years, with -$5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued fell 7109.33% year-over-year to -$5.4 million, compared with a TTM value of $10.0 million through Sep 2025, up 8773.45%, and an annual FY2024 reading of $75000.0, down 40.48% over the prior year.
  • Shares Issued was -$5.4 million for Q3 2025 at Oncology Institute, down from $15.4 million in the prior quarter.
  • Across five years, Shares Issued topped out at $15.4 million in Q1 2025 and bottomed at -$5.4 million in Q3 2025.
  • Average Shares Issued over 4 years is $1.2 million, with a median of $75000.0 recorded in 2024.
  • The sharpest move saw Shares Issued crashed 33.63% in 2024, then plummeted 7109.33% in 2025.
  • Year by year, Shares Issued stood at $442000.0 in 2022, then crashed by 74.43% to $113000.0 in 2023, then tumbled by 33.63% to $75000.0 in 2024, then tumbled by 7309.33% to -$5.4 million in 2025.
  • Business Quant data shows Shares Issued for TOI at -$5.4 million in Q3 2025, $15.4 million in Q1 2025, and $75000.0 in Q4 2024.